SPG5 and multiple sclerosis: Clinical and genetic overlap?(352 views) Criscuolo C, Carbone R, Lieto M, Peluso S, Guacci A, Filla A, Quarantelli M, Lanzillo R, Brescia Morra V, De Michele G
Department of Neurosciences, Reproductive Sciences and Odontostomatology 'Federico II' University of Naples Naples Italy
Biostructure and Bioimaging Institute National Research Council Naples Italy
Universita degli Studi di Napoli Federico II
Consiglio Nazionale delle Ricerche
References: Tsaousidou, M.K., Ouahchi, K., Warner, T.T., Sequence alterations within CYP7B1 implicate defective cholesterol homeostasis in motor-neuron degeneration (2008) Am J Hum Genet, 82, pp. 510-51
Criscuolo, C., Filla, A., Coppola, G., Two novel CYP7B1 mutations in Italian families with SPG5: a clinical and genetic study (2009) J Neurol, 256, pp. 1252-1257
Iccolella, M., Santorelli, F.M., Biancheri, R., Rossi, A., SPG5-related spastic paraplegia and white matter abnormalities (2009) Neuromuscul Disord, 19, pp. 507-508
Theofilopoulos, S., Griffiths, W.J., Crick, P.J., Cholestenoic acids regulate motor neuron survival via liver X receptors (2014) J Clin Invest, 124, pp. 4829-4842
Polman, C.H., Reingold, S.C., Banwell, B., Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria (2011) Ann Neurol, 69, pp. 292-302
Lublin, F.D., Reingold, S.C., Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis (1996) Neurology, 46, pp. 907-911
Roxburgh, R.H., Seaman, S.R., Masterman, T., Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity (2005) Neurology, 64, pp. 1144-1151
Compston, A., Coles, A., Multiple sclerosis (2008) Lancet, 372, pp. 1502-1517
Russell, W.D., Fifty years of advances in bile acid synthesis and metabolism (2009) J Lipid Res, 50, pp. 120-125
Mangalam, A., Poisson, L., Nemutlu, E., Profile of circulatory metabolites in a relapsing-remitting animal model of multiple sclerosis using global metabolomics (2013) J Clin Cell Immunol, 30, p. 4
Wang, L., Schuster, G.U., Hultenby, K., Zhang, Q., Andersson, S., Gustafsson, J.A., Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration (2002) Proc Natl Acad Sci USA, 99, pp. 13878-13883
Hindinger, C., Hinton, D.R., Kirwin, S.J., Liver X receptor activation decreases the severity of experimental autoimmune encephalomyelitis (2006) J Neurosci Res, 84, pp. 1225-1234
Kim, H.J., Fan, X., Gabbi, C., Liver X receptor (LXR): a link between beta-sitosterol and amyotrophic lateral sclerosis-Parkinson's dementia (2008) Proc Natl Acad Sci USA, 105, pp. 2094-2099
Walcher, D., Kümmel, A., Kehrle, B., LXR activation reduces proinflammatory cytokine expression in human CD4-positive lymphocytes (2006) Arterioscler Thromb Vasc Biol, 26, pp. 1022-1028
Didonna, A., Oksenberg, J.R., Genetic determinants of risk and progression in multiple sclerosis (2015) Clin Chim Acta, 449, pp. 16-22
Sellebjerg, F., Søndergaard, H.B., Koch-Henriksen, N., Sørensen, P.S., Oturai, A.B., Prediction of response to interferon therapy in multiple sclerosis (2014) Acta Neurol Scand, 130, pp. 268-275
Møller, M., Søndergaard, H.B., Koch-Henriksen, N., Sørensen, P.S., Sellebjerg, F., Oturai, A.B., The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis (2014) Acta Neurol Scand, 129, pp. 27-31
Lin, R., Taylor, B.V., Charlesworth, J., Modulating effects of WT1 on interferon-β-vitamin D association in MS (2015) Acta Neurol Scand, 131, pp. 231-239
Sawcer, S., Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis (2011) Nature, 476, pp. 214-219. , International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2
Ramagopalan, S.V., Dyment, D.A., Cader, M.Z., Rare variants in the CYP27B1 gene are associated with multiple sclerosis (2011) Ann Neurol, 70, pp. 881-886
SPG5 and multiple sclerosis: Clinical and genetic overlap?